Search

Your search keyword '"Loeff, Floris"' showing total 136 results
Start Over Author "Loeff, Floris"
136 results on '"Loeff, Floris"'

1. Belimumab concentration measurements using a homologous anti-idiotype immunoassay

Author

Loeff, Floris C., Parodis, Ioannis, Walhelm, Tomas, Jönsen, Andreas, Nikolopoulos, Dionysis, Sjöwall, Christopher, Bengtsson, Anders A., Kos, Dorien, van Leeuwen, Astrid, van den Broek, Bryan, Dijk, Lisanne, Jeremiasse, Jorn, Blomjous, Birgit S., Voskuyl, Alexandre E., Wolbink, Gerrit Jan, Bultink, Irene E. M., Rispens, Theo, Loeff, Floris C., Parodis, Ioannis, Walhelm, Tomas, Jönsen, Andreas, Nikolopoulos, Dionysis, Sjöwall, Christopher, Bengtsson, Anders A., Kos, Dorien, van Leeuwen, Astrid, van den Broek, Bryan, Dijk, Lisanne, Jeremiasse, Jorn, Blomjous, Birgit S., Voskuyl, Alexandre E., Wolbink, Gerrit Jan, Bultink, Irene E. M., and Rispens, Theo

Abstract

Monitoring belimumab concentrations in patients can be a valuable tool for assessing treatment response and for personalizing drug doses. Various assay formats may be used to measure concentrations of therapeutic monoclonal antibodies. A particularly useful format involves the use of anti-idiotype monoclonal antibodies, selected to be highly specific to the antibody of interest. Here, we describe the development of a specific, high-affinity anti-idiotype antibody to belimumab, and the application of this antibody in a homologous sandwich ELISA to measure belimumab concentrations., IP is supported by grants from the Swedish Rheumatism Association (R-969696), King Gustaf V's 80-year Foundation (FAI-2020-0741), Swedish Society of Medicine (SLS-974449), Nyckelfonden (OLL-974804), Professor Nanna Svartz Foundation (2021-00436), Ulla and Roland Gustafsson Foundation (2021-26), Region Stockholm (FoUI-955483), and Karolinska Institutet.

Published
2024
Full Text
View/download PDF

2. Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study

Author

Barker, Jonathan, Benham, Marilyn, Burden, David, Evans, Ian, Griffiths, Christopher, Hussain, Sagair, Kirby, Brian, Lawson, Linda, Mason, Kayleigh, McElhone, Kathleen, Murphy, Ruth, Ormerod, Anthony, Owen, Caroline, Reynolds, Nick, Smith, Catherine, Warren, Richard, Barker, Jonathan N.W.N., Barnes, Michael R., Burden, A. David, DiMeglio, Paola, Emsley, Richard, Evans, Andrea, Griffiths, Christopher E.M., Payne, Katherine, Reynolds, Nick J., Smith, Catherine H., Stocken, Deborah, Warren, Richard B., Loeff, Floris C., Tsakok, Teresa, Dijk, Lisanne, Hart, Margreet H., Duckworth, Michael, Baudry, David, Russell, Alice, Dand, Nick, van Leeuwen, Astrid, de Vries, Annick, Bloem, Karien, Wolbink, Gerrit Jan, and Rispens, Theo

Published
2020
Full Text
View/download PDF

7. Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease

Author

Otten, Antonius T, primary, van der Meulen, Hedwig H, additional, Steenhuis, Maurice, additional, Loeff, Floris C, additional, Touw, Daan J, additional, Kosterink, Jos G W, additional, Frijlink, Henderik W, additional, Rispens, Theo, additional, Dijkstra, Gerard, additional, Visschedijk, Marijn C, additional, and Bourgonje, Arno R, additional

Published
2023
Full Text
View/download PDF

8. Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspectives

Author

Smeijsters, Erin H., primary, van der Elst, Kim C. M., additional, Visch, Amy, additional, Göbel, Camiel, additional, Loeff, Floris C., additional, Rispens, Theo, additional, Huitema, Alwin D. R., additional, van Luin, Matthijs, additional, and El Amrani, Mohsin, additional

Published
2023
Full Text
View/download PDF

19. Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspectives

Author

Apotheek Opleiding, Apotheek Klinische Farmacie, Apotheek O&O&O, Cancer, Apotheek KF TDM, Smeijsters, Erin H, van der Elst, Kim C M, Visch, Amy, Göbel, Camiel, Loeff, Floris C, Rispens, Theo, Huitema, Alwin D R, van Luin, Matthijs, El Amrani, Mohsin, Apotheek Opleiding, Apotheek Klinische Farmacie, Apotheek O&O&O, Cancer, Apotheek KF TDM, Smeijsters, Erin H, van der Elst, Kim C M, Visch, Amy, Göbel, Camiel, Loeff, Floris C, Rispens, Theo, Huitema, Alwin D R, van Luin, Matthijs, and El Amrani, Mohsin

Published
2023

20. Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove

Author

Tsakok, Teresa, primary, Saklatvala, Jake, additional, Rispens, Theo, additional, Loeff, Floris C., additional, de Vries, Annick, additional, Allen, Michael H., additional, Barbosa, Ines A., additional, Baudry, David, additional, Dasandi, Tejus, additional, Duckworth, Michael, additional, Meynell, Freya, additional, Russell, Alice, additional, Chapman, Anna, additional, McBride, Sandy, additional, McKenna, Kevin, additional, Perera, Gayathri, additional, Ramsay, Helen, additional, Ramesh, Raakhee, additional, Sands, Kathleen, additional, Shipman, Alexa, additional, Burden, A. David, additional, Griffiths, Christopher E.M., additional, Reynolds, Nick J., additional, Warren, Richard B., additional, Mahil, Satveer, additional, Barker, Jonathan, additional, Dand, Nick, additional, Smith, Catherine, additional, and Simpson, Michael A., additional

Published
2023
Full Text
View/download PDF

22. Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis

Author

Spekhorst, Lotte S., primary, de Graaf, Marlies, additional, Loeff, Floris, additional, Zuithoff, Nicolaas P. A., additional, Bakker, Daphne, additional, Boesjes, Celeste M., additional, Thijs, Judith, additional, Achten, Roselie, additional, van Wijk, Femke, additional, Rispens, Theo, additional, and de Bruin-Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

25. ESDR126 - Serum dupilumab levels after 16 weeks of treatment are not associated with treatment response or side effects in atopic dermatitis patients

Author

Spekhorst, Lotte, primary, de Graaf, Marlies, primary, Loeff, Floris, primary, Zuithoff, Nicolaas, primary, Bakker, Daphne, primary, Boesjes, Celeste, primary, Thijs, Judith, primary, Achten, Roselie, primary, van Wijk, Femke, primary, Rispens, Theo, primary, and de Bruin-Weller, Marjolein, primary

Published
2022
Full Text
View/download PDF

26. Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Author

Spekhorst, Lotte S., primary, Bakker, Daphne, additional, Drylewicz, Julia, additional, Rispens, Theo, additional, Loeff, Floris, additional, Boesjes, Celeste M., additional, Thijs, Judith, additional, Romeijn, Geertruida L. E., additional, Loman, Laura, additional, Schuttelaar, Marie‐Louise, additional, van Wijk, Femke, additional, de Graaf, Marlies, additional, and de Bruin‐Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

27. Association of Serum Dupilumab Levels at 16 Weeks with Treatment Response and Adverse Effects in Patients with Atopic Dermatitis: A Prospective Clinical Cohort Study from the BioDay Registry

Author

MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Spekhorst, Lotte S., De Graaf, Marlies, Loeff, Floris, Zuithoff, Nicolaas P.A., Bakker, Daphne, Boesjes, Celeste M., Thijs, Judith, Achten, Roselie, Van Wijk, Femke, Rispens, Theo, De Bruin-Weller, Marjolein S., MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Spekhorst, Lotte S., De Graaf, Marlies, Loeff, Floris, Zuithoff, Nicolaas P.A., Bakker, Daphne, Boesjes, Celeste M., Thijs, Judith, Achten, Roselie, Van Wijk, Femke, Rispens, Theo, and De Bruin-Weller, Marjolein S.

Published
2022

28. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, CTI Computational Immunology Core, CTI Van Wijk, Child Health, Spekhorst, Lotte S, Bakker, Daphne, Drylewicz, Julia, Rispens, Theo, Loeff, Floris, Boesjes, Celeste M, Thijs, Judith, Romeijn, Geertruida L E, Loman, Laura, Schuttelaar, Marie-Louise, van Wijk, Femke, de Graaf, Marlies, de Bruin-Weller, Marjolein S, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, CTI Computational Immunology Core, CTI Van Wijk, Child Health, Spekhorst, Lotte S, Bakker, Daphne, Drylewicz, Julia, Rispens, Theo, Loeff, Floris, Boesjes, Celeste M, Thijs, Judith, Romeijn, Geertruida L E, Loman, Laura, Schuttelaar, Marie-Louise, van Wijk, Femke, de Graaf, Marlies, and de Bruin-Weller, Marjolein S

Published
2022

29. Fingerprick blood samples to measure serum natalizumab concentrations.

Author

Toorop, Alyssa A, Steenhuis, Maurice, Loeff, Floris C, Weijers, Suzanne S, Killestein, Joep, Rispens, Theo, and Kempen, Zoé LE van

Subjects
NATALIZUMAB, BLOOD sampling, DRUG monitoring, MULTIPLE sclerosis, PHYSICIANS
Abstract

Background: Natalizumab via subcutaneous administration was recently approved for patients with multiple sclerosis. Objective: In light of personalized extended dosing, in which treatment intervals are prolonged to a concentration cut-off, it would be preferable to measure natalizumab drug concentrations in capillary blood. Methods: In this cross-sectional study in patients treated with intravenous (IV) natalizumab, capillary blood samples by fingerprick and venous blood samples were collected in 30 participants prior to IV administration of natalizumab. Results: Natalizumab concentrations were similar with a mean bias of −0.36 μg/mL (95% CI: 1.3 to −2 μg/mL). Conclusions: This study shows that physicians can monitor natalizumab drug concentrations by a fingerprick, which could be used for personalized extended dosing. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study

Author

Boekel, Laura, primary, Hooijberg, Femke, additional, Vogelzang, Erik H, additional, Besten, Yaëlle R, additional, Leeuw, Maureen, additional, Atiqi, Sadaf, additional, van Vollenhoven, Ronald F, additional, Wijbrandts, Carla A, additional, Gerritsen, Martijn, additional, Krieckaert, C, additional, Dijkshoorn, Bas, additional, Bakhlakh, Siham, additional, Crooijmans, Juliette J, additional, Voskuyl, Alexandre, additional, van der Horst-Bruinsma, Irene E, additional, Lems, Willem, additional, Kuijpers, Taco W, additional, van Ham, S Marieke, additional, Wieske, Luuk, additional, Eftimov, Filip, additional, Kummer, Laura Y, additional, van Dam, PJ Koos, additional, Stalman, Eileen W, additional, Steenhuis, Maurice, additional, Keijzer, Sofie, additional, Cristianawati, Olvi, additional, Keijser, Jim, additional, Loeff, Floris C, additional, Tas, Sander W, additional, Nurmohamed, Michael T, additional, Boers, Maarten, additional, Rispens, Theo, additional, and Wolbink, Gertjan, additional

Published
2022
Full Text
View/download PDF

31. Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis.

Author

van Kempen, Zoé L. E., Hogenboom, Laura, Toorop, Alyssa A., Steenhuis, Maurice, Stalman, Eileen W., Kummer, Laura Y. L., van Dam, Koos P. J., Bloem, Karien, ten Brinke, Anja, van Ham, S. Marieke, Kuijpers, Taco W., Wolbink, Gerrit J., Loeff, Floris C., Wieske, Luuk, Eftimov, Filip, Rispens, Theo, Strijbis, Eva M. M., and Killestein, Joep

Subjects
MULTIPLE sclerosis, SARS-CoV-2, VACCINATION, HUMORAL immunity, MONOCLONAL antibodies
Abstract

Ocrelizumab, an anti‐CD20 monoclonal antibody, counteracts induction of humoral immune responses after severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccinations in patients with multiple sclerosis (MS). We aimed to assess if serum ocrelizumab concentration measured at the time of vaccination could predict the humoral response after SARS‐CoV‐2 vaccination. In 52 patients with MS, we found ocrelizumab concentration at the time of vaccination to be a good predictor for SARS‐CoV‐2 IgG anti‐RBD titers after vaccination (comparable to B‐cell count). As the course of ocrelizumab concentration may be predicted using pharmacokinetic models, this may be a superior biomarker to guide optimal timing for vaccinations in B‐cell depleted patients with MS. ANN NEUROL 2023;93:103–108 [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors

Author

Steenhuis, Maurice, van Mierlo, Gerard, Derksen, Ninotska Il, Ooijevaar-de Heer, Pleuni, Kruithof, Simone, Loeff, Floris L, Berkhout, Lea C, Linty, Federica, Reusken, Chantal, Reimerink, Johan, Hogema, Boris, Zaaijer, Hans, van de Watering, Leo, Swaneveld, Francis, van Gils, Marit J, Bosch, Berend Jan, van Ham, S Marieke, Ten Brinke, Anja, Vidarsson, Gestur, van der Schoot, Ellen C, Rispens, Theo, Steenhuis, Maurice, van Mierlo, Gerard, Derksen, Ninotska Il, Ooijevaar-de Heer, Pleuni, Kruithof, Simone, Loeff, Floris L, Berkhout, Lea C, Linty, Federica, Reusken, Chantal, Reimerink, Johan, Hogema, Boris, Zaaijer, Hans, van de Watering, Leo, Swaneveld, Francis, van Gils, Marit J, Bosch, Berend Jan, van Ham, S Marieke, Ten Brinke, Anja, Vidarsson, Gestur, van der Schoot, Ellen C, and Rispens, Theo

Abstract

Objectives: Characterisation of the human antibody response to SARS-CoV-2 infection is vital for serosurveillance purposes and for treatment options such as transfusion with convalescent plasma or immunoglobulin products derived from convalescent plasma. In this study, we longitudinally and quantitatively analysed antibody responses in RT-PCR-positive SARS-CoV-2 convalescent adults during the first 250 days after onset of symptoms.Methods: We measured antibody responses to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and the nucleocapsid protein in 844 longitudinal samples from 151 RT-PCR-positive SARS-CoV-2 convalescent adults. With a median of 5 (range 2-18) samples per individual, this allowed quantitative analysis of individual longitudinal antibody profiles. Kinetic profiles were analysed by mixed-effects modelling.Results: All donors were seropositive at the first sampling moment, and only one donor seroreverted during follow-up analysis. Anti-RBD IgG and anti-nucleocapsid IgG levels declined with median half-lives of 62 and 59 days, respectively, 2-5 months after symptom onset, and several-fold variation in half-lives of individuals was observed. The rate of decline of antibody levels diminished during extended follow-up, which points towards long-term immunological memory. The magnitude of the anti-RBD IgG response correlated well with neutralisation capacity measured in a classic plaque reduction assay and in an in-house developed competitive assay.Conclusion: The result of this study gives valuable insight into the long-term longitudinal response of antibodies to SARS-CoV-2.

Published
2021

33. Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors

Author

Virologie, dI&I I&I-1, Steenhuis, Maurice, van Mierlo, Gerard, Derksen, Ninotska Il, Ooijevaar-de Heer, Pleuni, Kruithof, Simone, Loeff, Floris L, Berkhout, Lea C, Linty, Federica, Reusken, Chantal, Reimerink, Johan, Hogema, Boris, Zaaijer, Hans, van de Watering, Leo, Swaneveld, Francis, van Gils, Marit J, Bosch, Berend Jan, van Ham, S Marieke, Ten Brinke, Anja, Vidarsson, Gestur, van der Schoot, Ellen C, Rispens, Theo, Virologie, dI&I I&I-1, Steenhuis, Maurice, van Mierlo, Gerard, Derksen, Ninotska Il, Ooijevaar-de Heer, Pleuni, Kruithof, Simone, Loeff, Floris L, Berkhout, Lea C, Linty, Federica, Reusken, Chantal, Reimerink, Johan, Hogema, Boris, Zaaijer, Hans, van de Watering, Leo, Swaneveld, Francis, van Gils, Marit J, Bosch, Berend Jan, van Ham, S Marieke, Ten Brinke, Anja, Vidarsson, Gestur, van der Schoot, Ellen C, and Rispens, Theo

Published
2021

34. The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation

Author

Berkhout, Lea C., Vogelzang, Erik H., Hart, Margreet M., Loeff, Floris C., Dijk, Lisanne, Derksen, Ninotska I.L., Wieringa, Roeland, van Leeuwen, W. Astrid, Krieckaert, Charlotte L.M., de Vries, Annick, Nurmohamed, Michael T., Wolbink, Gerrit J., Rispens, Theo, AII - Inflammatory diseases, ACS - Atherosclerosis & ischemic syndromes, Rheumatology, Graduate School, and Landsteiner Laboratory

Subjects
Rheumatology, Immunology, Immunology and Allergy, humanities
Abstract

OBJECTIVES: Tumour necrosis factor (TNF) inhibitors like certolizumab, elicit an immunogenic response leading to the formation of anti-drug antibodies (ADAs). We sought to mechanistically investigate the relationship between certolizumab concentrations, ADAs, and the effective TNF neutralising capacity in sera of rheumatoid arthritis (RA) patients. TNF neutralising capacity of certolizumab was compared to the neutralising capacity of adalimumab. METHODS: Serum samples were collected from 40 consecutive certolizumab-treated RA patients at baseline and 4, 16, 28 and 52 weeks after treatment initiation [Dutch Trial Register NTR (Nederlands Trial Register) Trial NL2824 no. 2965]. Certolizumab concentration and ADA titre were measured with a certolizumab bridging enzyme-linked immunosorbent assay (ELISA) and a drug-tolerant radioimmunoassay (RIA), respectively. TNF neutralisation by certolizumab and adalimumab, in presence or absence of ADAs, was analysed with the TNF-sensitive WEHI bioassay. RESULTS: Despite a high incidence of ADAs during one year of follow-up (65%; 26/40 patients), certolizumab levels of >10 μg/ml were measured in most patients. The capacity for TNF neutralisation highly correlated with certolizumab serum concentration, whereas no association with ADAs was observed. Similar results were obtained for adalimumab. The relative in vitro neutralising potency was higher for certolizumab compared to adalimumab. CONCLUSIONS: Anti-certolizumab antibodies were detected in a large proportion of patients, but in most cases where ADAs were detected, certolizumab was also present in high concentrations, directly correlating with in vitro neutralising capacity. These results indicate that measurement of certolizumab drug levels, rather than ADAs, have direct clinical significance.

Published
2020

35. Using real‐world data to guide ustekinumab dosing strategies for psoriasis: a prospective pharmacokinetic‐pharmacodynamic study

Author

Pan, Shan, Tsakok, Teresa, Dand, Nick, Lonsdale, Dagan O., Loeff, Floris C., Bloem, Karien, de Vries, Annick, Baudry, David, Duckworth, Michael, Mahil, Satveer, Pushpa‐Rajah, Angela, Russell, Alice, Alsharqi, Ali, Becher, Gabrielle, Murphy, Ruth, Wahie, Shyamal, Wright, Andrew, Griffiths, Christopher E.M., Reynolds, Nick J., Barker, Jonathan, Warren, Richard B., Burden, A. David, Rispens, Theo, Standing, Joseph F., Smith, Catherine H., Benham, Marilyn, Evans, Ian, Hussain, Sagair, Kirby, Brian, Lawson, Linda, Mason, Kayleigh, McElhone, Kathleen, Ormerod, Anthony, Owen, Caroline, Barnes, Michael R., Di Meglio, Paola, Emsley, Richard, Evans, Andrea, and Payne, Katherine

Abstract

Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real‐world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the first‐line therapeutic antibody ustekinumab. The impact of differing dosing strategies on response was explored. Data were collected from a UK prospective multicenter observational cohort (491 patients on ustekinumab monotherapy, drug levels, and anti‐drug antibody measurements on 797 serum samples, 1,590 measurements of Psoriasis Area Severity Index (PASI)). Ustekinumab PKs were described with a linear one‐compartment model. A maximum effect (Emax) model inhibited progression of psoriatic skin lesions in the turnover PD mechanism describing PASI evolution while on treatment. A mixture model on half‐maximal effective concentration identified a potential nonresponder group, with simulations suggesting that, in future, the model could be incorporated into a Bayesian therapeutic drug monitoring “dashboard” to individualize dosing and improve treatment outcomes.

Published
2020

36. Comprehensive evaluation of microneedle‐based intradermal adalimumab delivery vs . subcutaneous administration: results of a randomized controlled clinical trial

Author

Jacobse, Justin, primary, Voorde, Wouter, additional, Tandon, Anushka, additional, Romeijn, Stefan G., additional, Grievink, Hendrika W., additional, Maaden, Koen, additional, Esdonk, Michiel J., additional, Moes, Dirk Jan A.R., additional, Loeff, Floris, additional, Bloem, Karien, additional, Vries, Annick, additional, Rispens, Theo, additional, Wolbink, Gertjan, additional, Kam, Marieke, additional, Ziagkos, Dimitrios, additional, Moerland, Matthijs, additional, Jiskoot, Wim, additional, Bouwstra, Joke, additional, Burggraaf, Jacobus, additional, Schrier, Lenneke, additional, Rissmann, Robert, additional, and Cate, Rebecca, additional

Published
2021
Full Text
View/download PDF

37. Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors

Author

Steenhuis, Maurice, primary, van Mierlo, Gerard, additional, Derksen, Ninotska I.L., additional, Ooijevaar-de Heer, Pleuni, additional, Kruithof, Simone, additional, Loeff, Floris L., additional, Berkhout, Lea C., additional, Linty, Federica, additional, Reusken, Chantal, additional, Reimerink, Johan, additional, Hogema, Boris, additional, Zaaijer, Hans, additional, van de Watering, Leo, additional, Swaneveld, Francis, additional, van Gils, Marit J., additional, Bosch, Berend Jan, additional, van Ham, Marieke, additional, Brinke, Anja ten, additional, Vidarsson, Gestur, additional, van der Schoot, Ellen C., additional, and Rispens, Theo, additional

Published
2021
Full Text
View/download PDF

38. Antibody Development and Disease Severity of Covid-19 in Non-Immunized Patients with Rheumatic Immune-Mediated Inflammatory Diseases: Data from a Prospective Cohort Study

Author

Boekel, Laura, primary, Hooijberg, Femke, additional, Vogelzang, Erik, additional, Besten, Yaëlle, additional, Leeuw, Maureen, additional, Atiqi, Sadaf, additional, van Vollenhoven, Ronald, additional, Wijbrandts, Carla A., additional, Gerritsen, Martijn, additional, Krieckaert, Charlotte, additional, Dijkshoorn, Bas, additional, Bakhlakh, Siham, additional, Crooijmans, Julliëtte J., additional, Voskuyl, Alexandre, additional, van der Horst-Bruinsma, Irene E., additional, Lems, Willem F., additional, Kuijpers, Taco, additional, van Ham, Marieke, additional, Wieske, Luuk, additional, Eftimov, Filip, additional, Kummer, Laura, additional, van Dam, Koos, additional, Stalman, Eileen, additional, Steenhuis, Maurice, additional, Keijzer, Sofie, additional, Cristianawati, Olvi, additional, Keijser, Jim, additional, Loeff, Floris, additional, Tas, Sander, additional, Nurmohamed, Michael, additional, Boers, Maarten, additional, Rispens, Theo, additional, and Wolbink, Gertjan, additional

Published
2021
Full Text
View/download PDF

40. Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study

Author

Loeff, Floris C., primary, Tsakok, Teresa, additional, Dijk, Lisanne, additional, Hart, Margreet H., additional, Duckworth, Michael, additional, Baudry, David, additional, Russell, Alice, additional, Dand, Nick, additional, van Leeuwen, Astrid, additional, Griffiths, Christopher E.M., additional, Reynolds, Nick J., additional, Barker, Jonathan, additional, Burden, A. David, additional, Warren, Richard B., additional, de Vries, Annick, additional, Bloem, Karien, additional, Wolbink, Gerrit Jan, additional, Smith, Catherine H., additional, Rispens, Theo, additional, Benham, Marilyn, additional, Burden, David, additional, Evans, Ian, additional, Griffiths, Christopher, additional, Hussain, Sagair, additional, Kirby, Brian, additional, Lawson, Linda, additional, Mason, Kayleigh, additional, McElhone, Kathleen, additional, Murphy, Ruth, additional, Ormerod, Anthony, additional, Owen, Caroline, additional, Reynolds, Nick, additional, Smith, Catherine, additional, Warren, Richard, additional, Barker, Jonathan N.W.N., additional, Barnes, Michael R., additional, DiMeglio, Paola, additional, Emsley, Richard, additional, Evans, Andrea, additional, Payne, Katherine, additional, and Stocken, Deborah, additional

Published
2020
Full Text
View/download PDF

41. Favourable pharmacokinetics of intradermal adalimumab over subcutaneous administration: results of a randomized controlled trial

Author

Jacobse, Justin, primary, Voorde, Wouter ten, additional, Tandon, Anushka, additional, Romeijn, Stefan, additional, Grievink, Hendrika, additional, Maaden, Koen van der, additional, Esdonk, Michiel van, additional, Moes, Dirk Jan, additional, Loeff, Floris, additional, Bloem, Karien, additional, Vries, Annick de, additional, Rispens, Theo, additional, Wolbink, Gertjan, additional, Kam, Marieke de, additional, Ziagkos, Dimitrios, additional, Moerland, Matthijs, additional, Jiskoot, Wim, additional, Bouwstra, Joke, additional, Burggraaf, Jacobus, additional, Rissmann, Robert, additional, Schrier, Lenneke, additional, and Cate, Rebecca Ten, additional

Published
2020
Full Text
View/download PDF

44. Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft

Author

Loeff, Floris C., primary, van Egmond, Esther H.M., additional, Moes, Dirk J.A.R., additional, Wijnands, Charissa, additional, Von Dem Borne, Peter A., additional, Veelken, Hendrik, additional, Falkenburg, J.H. Frederik, additional, Jedema, Inge, additional, and Halkes, Constantijn J.M., additional

Published
2019
Full Text
View/download PDF

45. Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19

Author

Vogelzang, Erik H., Loeff, Floris C., Derksen, Ninotska I. L., Kruithof, Simone, Ooijevaar-de Heer, Pleuni, van Mierlo, Gerard, Linty, Federica, Mok, Juk Yee, van Esch, Wim, Vlaar, Alexander P. J., de Bruin, Sanne, Seppen, Bart, Leeuw, Maureen, van Oudheusden, Anne J. G., Buiting, Anton G. M., Jim, Kin Ki, Vrielink, Hans, Swaneveld, Francis, Vidarsson, Gestur, van der Schoot, C. Ellen, Wever, Peter C., Li, Wentao, van Kuppeveld, Frank, Murk, Jean-Luc, Bosch, Berend Jan, Wolbink, Gerrit-Jan, Rispens, Theo, Harris, Vanessa C., Hollmann, Markus W., Medical Microbiology and Infection Prevention, AII - Inflammatory diseases, Rheumatology, APH - Methodology, APH - Societal Participation & Health, Intensive Care Medicine, ACS - Microcirculation, Graduate School, ACS - Pulmonary hypertension & thrombosis, Landsteiner Laboratory, AII - Amsterdam institute for Infection and Immunity, APH - Global Health, APH - Health Behaviors & Chronic Diseases, Global Health, ACS - Heart failure & arrhythmias, and Anesthesiology

Subjects
Adult, Male, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), COVID-19/diagnosis, Hospitalized patients, media_common.quotation_subject, medicine.medical_treatment, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, Immunologic Tests, Antibodies, Viral, Antibodies, SARS-CoV-2/immunology, COVID-19 Serological Testing, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Taverne, medicine, Immunology and Allergy, Seroprevalence, Humans, Antibodies, Viral/immunology, Seroconversion, Viral/immunology, media_common, Nucleocapsid Proteins/immunology, biology, SARS-CoV-2, business.industry, Convalescence, Antibody titer, COVID-19, Nucleocapsid Proteins, Middle Aged, Titer, Antibody response, COVID-19 Nucleic Acid Testing, Antibody Formation, biology.protein, Plasmapheresis, Female, Antibody, business, 030215 immunology
Abstract

Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infections often cause only mild disease that may evoke relatively low Ab titers compared with patients admitted to hospitals. Generally, total Ab bridging assays combine good sensitivity with high specificity. Therefore, we developed sensitive total Ab bridging assays for detection of SARS-CoV-2 Abs to the receptor-binding domain (RBD) and nucleocapsid protein in addition to conventional isotype-specific assays. Ab kinetics was assessed in PCR-confirmed, hospitalized coronavirus disease 2019 (COVID-19) patients (n = 41) and three populations of patients with COVID-19 symptoms not requiring hospital admission: PCR-confirmed convalescent plasmapheresis donors (n = 182), PCR-confirmed hospital care workers (n = 47), and a group of longitudinally sampled symptomatic individuals highly suspect of COVID-19 (n = 14). In nonhospitalized patients, the Ab response to RBD is weaker but follows similar kinetics, as has been observed in hospitalized patients. Across populations, the RBD bridging assay identified most patients correctly as seropositive. In 11/14 of the COVID-19–suspect cases, seroconversion in the RBD bridging assay could be demonstrated before day 12; nucleocapsid protein Abs emerged less consistently. Furthermore, we demonstrated the feasibility of finger-prick sampling for Ab detection against SARS-CoV-2 using these assays. In conclusion, the developed bridging assays reliably detect SARS-CoV-2 Abs in hospitalized and nonhospitalized patients and are therefore well suited to conduct seroprevalence studies.

Published
2020

46. Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation ofPIGHexpression

Author

Loeff, Floris C., primary, Rijs, Kevin, additional, van Egmond, Esther H. M., additional, Zoutman, Willem H., additional, Qiao, Xiaohang, additional, Kroes, Wilhelmina G. M., additional, Veld, Sabrina A. J., additional, Griffioen, Marieke, additional, Vermeer, Maarten H., additional, Neefjes, Jacques, additional, Frederik Falkenburg, J. H., additional, Halkes, Constantijn J. M., additional, and Jedema, Inge, additional

Published
2018
Full Text
View/download PDF

47. High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor−/CD52− T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell–Depleted Allogeneic Stem Cell Transplantation

Author

Loeff, Floris C., primary, Falkenburg, J. H. Frederik, additional, Hageman, Lois, additional, Huisman, Wesley, additional, Veld, Sabrina A. J., additional, van Egmond, H. M. Esther, additional, van de Meent, Marian, additional, von dem Borne, Peter A., additional, Veelken, Hendrik, additional, Halkes, Constantijn J. M., additional, and Jedema, Inge, additional

Published
2018
Full Text
View/download PDF

49. Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.

Author

Tsakok, Teresa, Wilson, Nina, Dand, Nick, Loeff, Floris C., Bloem, Karien, Baudry, David, Duckworth, Michael, Pan, Shan, Pushpa-Rajah, Angela, Standing, Joseph F., de Vries, Annick, Alsharqi, Ali, Becher, Gabrielle, Murphy, Ruth, Wahie, Shyamal, Wright, Andrew, Griffiths, Christopher E. M., Reynolds, Nick J., Barker, Jonathan, and Warren, Richard B.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results